Potential benefit of lamotrigine in managing ketamine use disorder

Medical Hypotheses

Volumn 87, Issue , 2016, Pages 97-100

  Huang, Ming Chyi ^a,b   Chen, Lian Yu ^a   Chen, Chih Ken ^c,d   Lin, Shih Ku ^a,b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; LAMOTRIGINE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT; TRIAZINE DERIVATIVE;

ABDOMINAL PAIN; ABSTINENCE; ADULT; ALCOHOL USE DISORDER; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; CYSTITIS; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG TOLERANCE; EPILEPSY; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HUMAN; KETAMINE USE DISORDER; MALE; PHYSICAL DISEASE; SCORING SYSTEM; SMOKING HABIT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME; ANIMAL; BIOLOGICAL MODEL; DRUG THERAPY; PATHOPHYSIOLOGY; PHENCYCLIDINE ABUSE; PSYCHOLOGY;

ADULT; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MALE; MODELS, BIOLOGICAL; PHENCYCLIDINE ABUSE; TRIAZINES;

EID: 84955734093     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.11.011     Document Type: Article

References (49)

1. Domino E.F. Taming the ketamine tiger. Anesthesiology 2010, 113:678-684.
2. White P.F., Way W.L., Trevor A.J. Ketamine-its pharmacology and therapeutic uses. Anesthesiology 1982, 56:119-136.
3. Krystal J.H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Weekly 2007, 137:215-216.
4. C.G. Abdallah, G. Sanacora, R.S. Duman, J.H. Krystal, Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics, Annu Rev Med (2014).
5. Petersen R.C., Stillman R.C. Phencyclidine: an overview. NIDA Res Monograp 1978, 1-17.
6. Morgan C.J., Monaghan L., Curran H.V. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004, 99:1450-1461.
7. Dillon P., Copeland J., Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003, 69:23-28.
8. Cheng W.C., Ng K.M., Chan K.K., Mok V.K., Cheung B.K. Roadside detection of impairment under the influence of ketamine-evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci Int 2007, 170:51-58.
9. Fang Y.X., Wang Y.B., Shi J., Liu Z.M., Lu L. Recent trends in drug abuse in China. Acta Pharmacol Sin 2006, 27:140-144.
10. Yen C.F., Hsu S.Y., Cheng C.P. Polysubstance use and its correlates in adolescent ecstasy users in Taiwan. Addict Behav 2007, 32:2286-2291.
11. Zukin S.R., Zukin R.S. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979, 76:5372-5376.
12. Johnson K.M., Snell L.D., Sacaan A.I., Jones S.M. Pharmacologic regulation of the NMDA receptor-ionophore complex. NIDA Res Monograp 1993, 133:13-39.
13. Sinner B., Graf B.M. Ketamine. Handb Exp Pharmacol 2008, 313-333.
14. Kohrs R., Durieux M.E. Ketamine: teaching an old drug new tricks. Anesthesia Analgesia 1998, 87:1186-1193.
15. Morgan C.J., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010, 105:121-133.
16. Chen W.Y., Huang M.C., Lin S.K. Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy 2014, 9:39.
17. Skeldon S.C., Goldenberg S.L. Urological complications of illicit drug use. Nat Rev Urol 2014, 11:169-177.
18. Tan S., Lam W.P., Wai M.S., Yu W.H., Yew D.T. Chronic ketamine administration modulates midbrain dopamine system in mice. PLoS One 2012, 7:e43947.
19. Jansen K.L., Darracot-Cankovic R. The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drug 2001, 33:151-158.
20. Muetzelfeldt L., Kamboj S.K., Rees H., Taylor J., Morgan C.J., Curran H.V. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 2008, 95:219-229.
21. Lu Y., France C.P., Woods J.H. Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. J Pharmacol Exp Therap 1992, 263:499-504.
22. Morgan C.J., Rees H., Curran H.V. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med 2008, 38:1331-1340.
23. Critchlow D.G. A case of ketamine dependence with discontinuation symptoms. Addiction 2006, 101:1212-1213.
24. Chen J.T., Chen R.M. Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression. Expert Opin Drug Metab Toxicol 2010, 6:273-281.
25. Morgan C.J., Curran H.V., Independent D. Scientific Committee on Ketamine use: a review. Addiction 2012, 107:27-38.
26. Lim D.K. Ketamine associated psychedelic effects and dependence. Singapore Med J 2003, 44:31-34.
27. O'Brien C.P. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005, 162:1423-1431.
28. Uys J.D., LaLumiere R.T. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Target 2008, 7:482-491.
29. Olive M.F., Cleva R.M., Kalivas P.W., Malcolm R.J. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012, 100:801-810.
30. Kalivas P.W., Volkow N.D. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry 2011, 16:974-986.
31. Uys J.D., Reissner K.J. Glutamatergic neuroplasticity in cocaine addiction. Progr Mol Biol Trans Sci 2011, 98:367-400.
32. Gass J.T., Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008, 75:218-265.
33. Calabrese J.R., Shelton M.D., Rapport D.J., Kimmel S.E., Elhaj O. Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry 2002, 63(Suppl. 10):18-22.
34. Rogawski M.A., Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004, 5:553-564.
35. Wang S.J., Sihra T.S., Gean P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 2001, 12:2255-2258.
36. Pisani A., Bonsi P., Martella G., et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45:719-728.
37. Sitges M., Chiu L.M., Guarneros A., Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 2007, 52:598-605.
38. Margolin A., Avants S.K., DePhilippis D., Kosten T.R. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am J Drug Alcohol Abuse 1998, 24:85-101.
39. Shamsi M., Hemme C., Beitman B. Reduction in cocaine craving in response to low-dose Lamotrigine in a 39-year-old African American MAN. Psychiatry 2006, 3:17.
40. Brown E.S., Nejtek V.A., Perantie D.C., Orsulak P.J., Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry 2003, 64:197-201.
41. Brown E.S., Perantie D.C., Dhanani N., Beard L., Orsulak P., Rush A.J. Lamotrigine for bipolar disorder and comorbid cocaine dependence. a replication and extension study. J Affect Disord 2006, 93:219-222.
42. Brown E.S., Sunderajan P., Hu L.T., Sowell S.M., Carmody T.J. A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology 2012, 37:2347-2354.
43. Rubio G., Lopez-Munoz F., Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 2006, 8:289-293.
44. Anand A., Charney D.S., Oren D.A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000, 57:270-276.
45. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008, 65:154-164.
46. Razoux F., Garcia R., Lena I. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens, Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 2007, 32:719-727.
47. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52:998-1007.
48. Trujillo K.A., Smith M.L., Sullivan B., Heller C.Y., Garcia C., Bates M. The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. ILAR J 2011, 52:366-378.
49. Takahata R., Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003, 28:1117-1124.